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Antisense oligonucleotides are compounds which hybridize to specific mRNAs and ultimately decrease the production of a protein associated with a disease (Crooke, 1995) . Currently, several antisense oligonucleotide compounds are in clinical trials for indications of cancer and inflammation and as antiviral agents (Crooke, 1996) . The potential efficacy and pharmacologic effects of these antisense phosphorothioate oligodeoxynucleotide (P=S ODN) molecules in the treatment of cancer have been demonstrated in in vivo tumor xenograft models (Yazaki et al., 1996) . The antisense activity of these compounds is demonstrated by decreases in specific mRNA and target proteins levels (Dean and McKay, 1994; Mandiyan et al., 1997; Yazaki et al., 1996) . In addition to the specific pharmacologic effects noted, P=S ODNs induce several toxicities in animal models that are not related to the inhibition of expression of the molecular target.
Toxicities induced by P=S ODN are in general independent of specific sequence and the molecular target and are considered to be related to the class of compound. These toxicities include activation of complement (Galbraith et al., 1994; Henry et al., 1997b) and inhibition of coagulation in monkeys (Henry et ai, 1997e) , lymphoproliferation in mice (Branda et al, 1993; Mclntyre era/., 1993; Monteith etal, 1997; Zhao et al, 1995) , and varying degrees of target organ toxicity in the kidney and liver (Henry et al., 1997a, d, f; Sarmiento et al, 1994) . These effects typically occur at doses substantially greater than the doses required to produce a pharmacologic effect on a molecular target.
One target for antisense therapy in the treatment of cancer is C-ra/kinase, because of its pivotal role as a regulatory protein in cell signaling during proliferation and its role in the development and maintenance of certain human malignancies. A P=S ODN, CGP 69846A, that is complementary to a sequence of human C-raf kinase mRNA has been identified (Monia et al, 1996a) . The antiproliferative effects of CGP 69846A were demonstrated in human tumor cells with concurrent decreases specifically in both C-raf kinase mRNA and protein levels, while A-ra/and H-ras were not altered (Monia et al., 1996a) . P=S ODNs containing mismatched sequences were included as controls and did not reduce mRNA or protein levels. The specificity of action and sequence specificity support an antisense mechanism and the potential role of targeting C-ra/for the treatment of cancer.
Currently, clinical studies are ongoing evaluating safety and efficacy of CGP 69846A in patients with various solid tumors and results of Phase I studies have recently been reported O'Dwyer et al., 1998) . With every other day intravenous infusions (three infusions per week) of CGP 69846A, stable disease was associated with a decrease in clinical markers for cancer and reductions in C-raf mRNA in circulating peripheral mononuclear cells O'Dwyer et al., 1998) . CGP 69846A was well tolerated in advanced-stage cancer patients O'Dwyer et al., 1998) .
In the present study, the toxicity of CGP 69846A was evaluated in mice and monkeys. Mice were administered iv doses as high as 100 mg/kg and monkeys were administered iv doses up to 10 mg/kg; the duration of dosing was 4 weeks. Because of species differences in gene sequences, CGP 69846A targeting human C-raf mRNA does not have activity in the mouse. Therefore, the murine sequence was obtained and a murine-specific antisense P=S ODN was synthesized. In toxicity studies in mice, both the human (CGP 69846A) and the murine (ISIS 11061) homologues were studied to fully characterize toxicity, including possible toxicologic effects associated with reductions in C-ra/expression, exaggerated pharmacology. Comparing the toxicity profile of CGP 69846A and ISIS 11061 (the murine homologue of CGP 69846A) afforded the opportunity to differentiate between the toxicities associated with the class effects of these compounds and the toxicities associated with prolonged inhibition of C-raf kinase. In addition, the pharmacokinetics and tissue distribution were characterized in these studies to relate exposure (tissue and plasma concentrations) with toxicity.
MATERIALS AND METHODS

Oligodeoxynucleotides
CGP 69846A (also known as ISIS 5132) and ISIS 11061 are P=S ODNs consisting of 20 nucleotides each. The specific sequences and the synthesis of P=S ODNs are discussed elsewhere (Cioffi el al., 1997) . The oligodeoxynucleotides were synthesized at Isis Pharmaceuticals and were greater than 90% full-length P=S ODN.
Pharmacology
Reduction in C-ra/expression by ISIS 11061 treatment was determined in CD-I mice purchased from Charles River Laboratories. ISIS 11061 was administered to four mice per group daily or every other day as an iv injection via the tail vein for a total of three doses at 100 mg/kg. Two additional groups received daily iv injections of 100 mg/kg of ISIS 5132 or saline (control). ISIS 5132, as the human-specific homologue, does not hybridize to the mouse C-raf mRNA and thus serves as a control oligodeoxynucleotide in the mouse. Mice were euthanized and tissue was collected 24 h after the last dose. In addition a specimen of liver tissue was collected from monkeys to assess C-raf kinase mRNA levels at the end of the 4 weeks of treatment in the toxicology study described below. Liver tissue from monkeys was collected 48 h after the last dose. All tissue was homogenized in ice-cold guanidinium HC1. Total RNA was isolated by centrifugation of the lysates over a cesium chloride gradient (Monia el al.. 1996a) . Northern analysis was conducted as previously described (Monia et al, 1996b) by hybridization to randomly primed 32 P-labeled full-length cDNA probes corresponding to human C-raf or human glyceraldehyde-3-phosphate dehydrogenase (G3PDH). RNA was quantitated using a Molecular Dynamic Phosphorlmager as described previously (Dean and McKay, 1994) .
Toxicology
Mouse. CD-1 mice were purchased from Charles River Laboratories and the study was performed by Pharmakon Research International (Dr. C. B. Spainhour). Mice were acclimated for approximately 10 days and were approximately 8 to 9 weeks old at initiation of the study. Upon receipt mice were housed individually in stainless-steel cages and given free access to water and aliquoted certified rodent chow. Groups of 10 male and 10 female mice (or 15 of each sex for the control and high-dose groups) were administered 0 (vehicle control), 0.8, 4, 20, or 100 mg/kg of CGP 69846A by iv injection every other day (qod) for 4 weeks (total of 14 doses). Another group of 5/sex was given injections of 10 mg/kg CGP 69846A on a daily basis, yielding a cumulative dose equivalent to the 20 mg/kg qod group. Two other groups of 10/sex received 20 or 100 mg/kg, qod, of the murine homologue, ISIS 11061. All dosing solutions were prepared from lyophilized bulk drug and formulated in phosphate-buffered saline, filter sterilized, and checked for concentration, sterility, and endotoxin. Dosing volume was 10 ml/kg. Two days after the last dose, all animals (except 5/sex in the control and 100 mg/kg dose groups of both CGP 69846A and ISIS 11061) were euthanized; the remaining animals in the control and high-dose groups were maintained for an additional 4-week period to evaluate reversal of any effects. A standard toxicological evaluation was performed which included daily clinical signs, weekly body weight and food consumption, and end of study ophthalmic exams, clinical pathology, organ weights, and complete gross necropsy on all animals and light microscopic examination of a full range of tissues.
Monkey. A 4-week study was performed in cynomolgus monkeys at Battelle Columbus Laboratory (Dr. R. R. Moutvic). The objective of the study was to assess the toxicity and toxicokinetics of CGP 69846A when administered by iv injection or infusion. Groups of five male and five female monkeys (control and high dose groups) or three per sex (low and mid dose) were dosed with 0 (vehicle control), 1, 3, or 10 mg/kg every other day for 27 days (total of 14 doses) by 2-h constant iv infusion. A fifth group of monkeys, three per sex, received a daily bolus iv injection of 1 mg/kg (over ~2 min). All animals were observed during infusion or following each injection. Blood pressure, heart rate, and electrocardiogram were monitored in ketamine-tranquilized animals. Cardiovascular parameters were collected prior to initiation of dosing and approximately 1 h postdosing 1 to 3 days before termination. Ophthalmic exams were conducted prior to initiation of dosing and prior to each animal's scheduled euthanization. Complete clinical pathology evaluations were conducted on all animals prior to the study and near the end of the dosing and recovery periods. In addition to routine clinical pathology sampling, blood samples for hematology, complement products (Bb split product), and coagulation were collected prior to dosing and at time points during infusion and 1 h after infusion/injection on Days 1, 13, and 27. Concentrations of CGP 69846A in plasma, as well as selected serum biochemistry or hematology parameters, were assessed on Days 1,13, and 27. At the end of the dosing period, three male and three female monkeys from each group were euthanized, and the remaining monkeys in the control and high-dose groups (two per sex) were maintained for an additional 4-week recovery period. At termination, all animals were subjected to a complete gross necropsy, the weights of major organs were recorded, and tissues were collected for histopathologic examination. The level of C-ra/kinase mRNA expression in the liver of mice receiving 0.9% NaCI (vehicle). 100 mg/kg of ISIS 11061 every day for three doses, 100 mg/kg of ISIS 11061 every other day (qod) for three doses, and 100 mg/kg of CGP 69846A every day for three doses is presented from a Northern analysis as the ratio of C-ra/kinase mRNA to G3PDH mRNA (normalized). Data represent mean values from four mice per treatment. Error bars represent standard deviation.
Toxicokinetics
Mouse. An additional group of male mice (three per dose per time point) were administered 0.8, 4, 20, and 100 mg/kg of CGP 69846A for assessment of plasma concentrations and tissue distribution. Blood samples and tissues were collected at selected time points from 2 min through 96 h after 1, 8, and 15 doses. Tissues collected and frozen for subsequent analysis included liver, kidney, mesenteric lymph nodes, skeletal muscle, heart, spleen, lungs, and skin.
Monkey. Blood was sampled for determination of plasma oligodeoxynucleotide concentrations at various time points following administration on Days 1,13, and 27 of the study. At euthanization (at the end of treatment) portions of the following organs were frozen for analysis of drug concentrations: liver, kidney, spleen, heart, lymph nodes, bone marrow, testes or ovaries, and pancreas.
Analysis of Plasma and Tissue Sample for Oligodeoxynucleotide
The method for extraction and analysis of CGP 69846A and the metabolites from tissues and plasma combined the extraction of oligodeoxynucleotides from tissues (Cossum el ai, 1993) with the solid-phase extraction method developed for nonradiolabeled analysis of P=S ODNs (Leeds el ai, 1996) .
RESULTS
Pharmacology
The effect of ISIS 11061 on C-ra/kinase mRNA expression in mice was assessed by comparing C-ra/kinase mRNA levels in mice administered saline, CGP 69846A, and ISIS 11061. All data were calculated (normalized) as the ratio of C-ra/kinase mRNA to G3PDH mRNA ( Fig. 1) . A dose of 100 mg/kg of ISIS 11061 administered as daily or every other day injections significantly reduced the C-ra/kinase expression in the liver of mice (Fig. 1) . The effect of ISIS 11061 was similar whether administered daily or every other day. The vehicle control and CGP 69846A (human homologue) had no effect on mouse C-ra/expression. Because CGP 69846A does not hybridize to mouse C-ra/mRNA, it would be a negative control (nonmatching sequence) indicating that the effect is dependent on the specific sequence. No inhibition of C-ra/ kinase mRNA expression was observed in the liver of monkeys at the end of 4 weeks of administration of doses up 10 mg/kg CGP 69846A (data not shown). However, a two-base mismatch exists between the human and the cynomolgus monkey sequences and multiple mismatches in sequences have been shown to significantly decrease the antisense activity (Ma and Calvo, 1996; Mandiyan et ai, 1997) . Thus, the mismatches in the sequence would reduce the chances of observing reductions of C-raf mRNA in monkeys.
Toxicology
Clinical Signs, Organ Weights, and Gross Observations
Mouse. By the third week of the study, the mice administered 100 mg/kg CGP 69846A were exhibiting generally poor health status which included distention of the abdomen, decreased activity, abnormal gait, tremors, and labored respiration. Nine of 30 mice (15/sex) died or were euthanized in moribund condition. There was no apparent gender difference in sensitivity. No effects on body weight were observed for any treatment group. The high-dose (100 mg/kg) groups of CGP 69846A, where clinical signs, morbidity, and mortality were observed, had no decrease in body weight (Fig. 2) , although food consumption was decreased in the high-dose group of CGP 69846A (Fig. 3) , consistent with the poor health status of these mice. The weight increase may have been due to the fluid build-up in the abdomen. No clinical signs were observed for lower dose groups. In comparison with the severe effects observed with CGP 69846A, ISIS 11061 was not lethal and clinical signs were minimal.
The mean weights of spleen and liver were increased (Table  1) . Organ weights from all other dose groups were within normal control ranges, except spleen weights which were significantly increased in both the 10 and the 20 mg/kg dose groups of CGP 69846A. Other organ weights, such as adrenals, brain, lungs, ovaries, and testes, were within control ranges for all dose groups.
Monkey. No animals died during the course of this study. No remarkable effects were observed for clinical signs, blood pressure, heart rate, ECG, opthalmic evaluation, body weights, and organ weights.
Clinical Chemistry and Hematology
Mouse. Serum transaminases were increased 10-to 19-fold in mice administered 100 mg/kg of either CGP 69846A or ISIS 11061 and reductions were observed in serum albumin (-30%), globulin (15 to 30%), and cholesterol (65 to 84%) (Table 2 ). Creatine phosphokinase (CPK) was also increased in the 100 mg/kg CGP 69846A dose group (Table 2) . These serum biochemistry changes were associated with histological changes in the liver and heart (see below). Serum chemistry parameters for mice receiving lower doses and electrolyte values for all treatment groups were within normal control ranges.
Several effects in hematological parameters were associated with administration of high doses of CGP 69846A and ISIS 11061 (Table 3) . White blood cell counts were increased in the high-dose groups and attributed primarily to increases in lymphocytes. Decreases in red blood cells, hematocrit, and hemoglobin were induced by the high dose (100 mg/kg) of CGP 69846A. Platelets were also significantly decreased in the 100 and 20 mg/kg CGP 69846A dose groups but not in the mice administered ISIS 11061.
Monkey.
No remarkable effects were observed for routine hematology, urinalysis, and serum chemistry. No treatmentrelated effects on hematology parameters were observed. At the end of infusion, activated partial thromboplastin time (APTT) was increased by 50 to 70% in the high dose (10 mg/kg) group (Fig. 4) . Increases in APTT were transient and were coincident with the rise and fall of plasma concentrations of CGP 69846A. The prolongation of APTT was unaffected by repeated administration (Dose 1 to 14, Fig. 4, middle) . No effects were observed on other coagulation parameters. Concentrations of the complement split product, Bb, were increased in the high dose (10 mg/kg) group indicating activation of the alternative pathway of complement (Fig. 4, top) . Activation of complement, defined as a Bb concentration >1.0 ig/ml, was associated with the peak plasma concentration of CGP 69846A (Fig. 4) . Plotting plasma concentrations and complement split product levels at various times during infusion yields an apparent threshold of approximately 35 /xg/ml of CGP 69846A for complement activation (Fig. 5) . The threshold was defined as the plasma concentration which when exceeded resulted in activation of complement in at least one monkey. A dose of at least 10 mg/kg administered as a 2-h iv infusion was necessary to produce a plasma concentration of CGP 69846A that exceeded the threshold and activated complement. In this study, activation of complement was not associated with adverse clinical signs. Alterations in complement, similar to increases in APTT, appear to be transient returning toward baseline levels within 3 h. Previous studies with P=S ODN compounds indicate levels of complement and prolongation of APTT return to normal within several hours of the end of infusion (Henry et al., 1997b, e) .
Histopathology
Mouse Hepatocellular changes were observed in mice administered 100 mg/kg of CGP 69846A or ISIS 11061. Liver effects were characterized by minimal to moderate eosinophilic hepatocytomegaly accompanied in most of the mice with a minimal to severe hepatocellular degeneration and minimal to moderate Kupffer cell hyperplasia (Table 4 ). The hepatic effects were consistent with the alterations in serum chemistry discussed previously. Neither the hepatocellular effects nor the serum biochemistry changes were observed in the lower dose groups (<20 mg/kg).
In mice, there was an alteration in white blood cell counts and mononuclear cell infiltrates in tissues and splenomegaly that reflect the characteristic immune stimulation observed after treatment of rodents with other P=S ODNs (Henry et al, 1997c; Monteith et al, 1997; Sarmiento et al, 1994) . These changes were most pronounced in mice administered 100 mg/kg and were less severe or absent in the lower dose groups. In mice receiving the high doses of CGP 69846A white blood cell counts were increased, splenomegaly was induced, and mild to moderate cellular infiltrates were present in multiple organs. In mice administered 20 mg/kg of CGP 69846A, these effects were characterized as mild splenomegaly and generally mild inflammation of the pancreas, salivary gland, exorbital lachrimal gland, lungs, skin, and genitourinary tract (Table 5) . Lower dose groups of CGP 69846A (<4 mg/kg) and the ISIS 11061 dose groups (20 and 100 mg/kg) did not induce mononuclear cell infiltration. Moderate degree of cellular infiltrates observed in the hearts of mice receiving 100 mg/kg CGP 69846A could be associated with the elevated CPK.
Other effects noted in mice treated with CGP 69846A include extramedullary hematopoiesis in the spleen and liver and an increase in bone marrow cellularity. These effects were limited to the high dose of CGP 69846A. Doses of 4 mg/kg every other day or 10 mg/kg daily by iv injection induced a slight exacerbation of the hepatic inflammation normally observed in mice. Effects of daily administration of 10 mg/kg versus every other day administration of 20 mg/kg demonstrated no clinical differences; however, cellular infiltrates were present in tissues of the latter group. After a 4-week recovery period, there was a complete or partial recovery of all treatment-related changes. A few mice in the recovery group that received CGP 69846A had some remaining evidence of treatment-related changes which included atrophy of acinar cells and/or the accumulations of mononuclear cells in the pancreas, salivary glands, and/or exorbital lachrimal glands.
Effects at 20 and 100 mg/kg of ISIS 11061 were qualitatively similar, albeit less pronounced, than those observed at the same dose levels of CGP 69846A. There were no toxicities associated with ISIS 11061 that differentiated it from CGP 69846A, and thus, there was no evidence of toxicity related to the administration of this pharmacologically active antisense oligodeoxynucleotide to mice.
Monkey
The histologic appearance of all tissues and organs was unremarkable, except the kidney. In the kidney, no alterations in histology were noted in sections stained with hematoxylin and eosin. However, tissue sections stained with toluidine blue for the purpose of identifying oligodeoxynucleotide had a dose-related increase in granules within the cytoplasm of renal proximal tubular epithelial cells from CGP 69846A-treated animals. No pathological effects on the glomeruli or renal tubules were evident microscopically, consistent with normal serum and urinary parameters. The lymphoid proliferation and mononuclear cell infiltrates (i.e., immune stimulation) of the type observed in mice was absent in monkeys treated with up to 10 mg/kg CGP 69846A, every other day, for 4 weeks.
Toxicokinetics
Mouse Plasma pharmacokinetic profiles of CGP 69846A were determined at doses of 4 and 20 mg/kg. The highest plasma drug concentrations (C max ) were detected in the first samples which were collected 2 min after dosing (Fig. 6) . The plasma kinetics for CGP 69846A after a single dose (Day 1) and 14 doses (Day 28) of 4 mg/kg were unchanged, while plasma concentrations of CGP 69846A following administration of 20 mg/kg increased approximately twofold after 15 doses over the values on Day 1 (Fig. 6) , suggesting alteration of drug clearance or disposition. The most significant toxicity was noted with doses of >20 mg/kg. The nonlinear plasma kinetics suggest saturation of uptake as dose increased.
The disposition of CGP 69846A from plasma was characterized by deposition into all tissues analyzed which included heart, liver, kidney, lung, spleen, and mesenteric lymph nodes. These data have been discussed in detail previously (Geary et al, 1997) . The kidney had the highest concentrations of CGP 69846A at 24 h after administration in all dose groups. The tissues with the highest concentrations of CGP 69846A were the kidney, liver, and lung and tissue concentrations increased from Day 1 to Day 28. These tissues also exhibited severe mononuclear cell infiltration or other histopathological alterations. Accumulation of oligodeoxynucleotides over the course of the treatment was not observed in other tissues (lymph nodes, heart, spleen), although a mild degree of cellular infiltrates or lymphoid hyperplasia was observed in these tissues.
Monkey
Plasma concentrations of oligodeoxynucleotide generally peaked at the end of the 2-h infusion for all doses (Fig. 4C) . After the end of infusion, plasma levels decreased rapidly and estimated plasma half-lives were approximately 30 to 85 min over the dose range of 1 to 10 mg/kg (Table 6 ). Plasma samples from the high dose group (10 mg/kg) just prior to dosing on Days 13 and 27 showed plasma concentrations near or below the limit of detection (0.07 /i,g/ml) suggesting that there was almost complete clearance from plasma by 48 h. The plasma concentration versus dose areas under the curve (AUCs) increased approximately 20-fold over a 10-fold range of doses (Fig. 7) . Peak plasma concentrations were nonlinear over the dose range, increasing approximately 15-to 20-fold over a 10-fold range of doses.
The kidney, specifically the cortex, had the highest concentration of CGP 69846A, followed by the liver, spleen, lymph Note, nd, not determined. Values in parentheses are standard deviations of the means. " Mean peak plasma concentration at 1 h during infusion. The concentration at 2 h was 2.0 /Ag/ml (±0.3). * Mean peak plasma concentration at 1 h during infusion. The concentration at 2 h was 1.8 /xg/ml (±1.0). nodes, lung, and heart (Fig. 8) . The concentration of CGP 69846A in pancreas, bone marrow, testes, and ovaries was below the limit of quantitation (0.1 /xg/g) at all doses. The concentration of oligodeoxynucleotide increased 6-fold in kidney as the dose increased 10-fold, while liver concentrations increased only 2-fold over the same dose range. The apparent saturation of distribution to these primary sites of P=S ODN deposition may account for the observed nonlinearity in plasma kinetics. In contrast, the CGP 69846A concentration in lymph nodes and spleen increased more than 10-fold over the dose range of 1 to 10 mg/kg.
DISCUSSION
Repeated injections of 100 mg/kg CGP 69846A for 4 weeks resulted in morbidity and mortality in mice. The exact cause of morbidity could not be determined but was probably related to the hepatotoxic effects observed in this high-dose group. These results differ from previous reports in which mice were administered other P=S ODNs by intraperitoneal injection where acute renal failure or tubular necrosis was considered the likely cause of death at doses >100 mg/kg (Sarmiento et al., 1994) . No tubular necrosis was evident in the present study with iv administration of doses up to 100 mg/kg. The hepatic effects and lack of renal toxicity are similar to findings observed with other P=S ODNs where doses have not exceeded 100 mg/kg (Henry et al, 1997f) . These data would suggest that doses > 100 mg/kg are required to induce renal effects in mice.
Administration of CGP 69846A to monkeys did not result in mortality or clinical signs. The primary effects in monkeys were dose-related transient increases in APTT and activation of the alternative pathway of complement (Henry et al., 1997b, e) . Prolongation of APTT parallels plasma concentrations of P=S ODN and was reversed as oligodeoxynucleotides were cleared from circulation. The increase in APTT was at most a 70% increase from baseline. There was no inhibitory effect on other coagulation indices. Inhibition of only APTT indicates an effect on the intrinsic clotting pathway which represents a single segment of the coagulation system (Henry et al., 1997e) . The transient prolongation of APTT has little clinical significance and can be easily monitored in clinical trials. Complement activation occurs in monkeys when the plasma concentration of intact CGP 69846A exceeded a threshold of -35 pig/ml; below this threshold no activation occurs. Activation of complement can be attenuated by reducing the peak plasma concentration of oligodeoxynucleotide which can be accomplished by slowing the rate of infusion (Henry et al., 1997b) . No clinical signs associated with complement activation occurred in monkeys, although complement activation has been associated with various hemodynamic and hematological abnormalities which, in rare instances, may become so severe as to result in cardiovascular collapse (Galbraith et al., 1994) . Complement activation has not been observed or characterized in rodents administered P=S ODNs.
Administration of CGP 69846A to mice for 4 weeks produced a spectrum of effects, collectively regarded as immune stimulation. There is a clear dose response for immune stimulation in mice and attendant clinical and pathologic alterations. At low doses (<4 mg/kg), the only evidence of immune stimulation was that hepatic inflammation, typically observed in control mice, was slightly exacerbated in the low-dose groups. The features of the observed immune stimulation include splenomegaly, lymphoid hyperplasia in spleen and lymph nodes, and multiple organ mononuclear cell infiltrates. The cellular infiltrates were most evident in liver, kidney, and lung. There were no signs of extensive parenchymal damage or organ dysfunction associated with the cellular infiltration with the exception of the liver in animals treated with 100 mg/kg of CGP 69846A. Immune stimulatory effects have been reported previously (Henry et ai, 1997c; Monteith et ai, 1997; Sarmiento et ai, 1994) and are probably related to the polyanionic composition of these compounds (Diamantstein and BlisteinWillinger, 1978; Diamantstein et ai, 1971; Homan et ai, 1972) . Polyanionic molecules, including P=S ODNs, are known to stimulate B-cell proliferation and some of the immune responses observed in rodents may be the result of this effect (Pisetsky and Reich, 1994) . The lymphocyte proliferative response is induced with other oligodeoxynucleotides in mice and rats and, hence, is thought to be related to the nonspecific effect of P=S ODN (Henry et ai, 1997c; Monteith et al, 1997) . Mononuclear cell infiltrates in the liver and spleen are associated with increased organ weights at the highest dose tested (100 mg/kg). The splenomegaly and mononuclear cellular infiltrates observed in mice were not observed in monkeys even though tissue concentrations of P=S ODN were comparable or greater in many tissues in the monkeys. Thus, the results from this and other studies demonstrate that rodents are much more sensitive to the immune stimulatory effects induced by treatment with P=S ODNs (Henry et ai, 1997d) .
There was a difference in the degree of immune stimulation between the 10 mg/kg daily dose group and 20 mg/kg every other day dose group. Although the same total dose was administered to mice over the 4 weeks, the 20 mg/kg dose induced significantly more immune stimulation. These data might suggest that the higher peak plasma concentrations and/or tissue concentrations of P=S ODN associated with less frequent administration of the higher dose are a factor in the induction of immune stimulation in mice. However, tissue concentrations of oligodeoxynucleotide are not the causative factor because tissue concentrations of oligodeoxynucleotide are comparable or greater in many tissues of monkeys compared to mice.
Immune stimulation in mice appeared dependent on nucleotide sequence, but has been demonstrated to be independent of pharmacological target (Monteith et ai, 1997) . While potency for immune stimulation varies for different P=S ODNs, immune stimulation occurs as a class effect of P=S ODNs (Monteith et ai, 1997) . ISIS 11061 produced a lesser degree of immune stimulation in mice than did CGP 69846A. The difference in immune stimulation is potentially linked to the stimulation of B-lymphocyte proliferation. The CpG motif and specific flanking 5'-purines and 3'-pyrimidines have been demonstrated as potent inducers of B-lymphocyte proliferation (Krieg et ai, 1995; Yamamoto et ai, 1994) , as well as potent stimulators of natural killer cells and interferon production (Kuramoto et ai, 1992; Shimada et ai, 1986; Tokunaga et ai, 1988; Yamamoto et ai, 1994) . Increased spleen weights and the associated histologic findings in the spleen were consistent with a stimulation of B-cells (Branda et al, 1993; Krieg et al, 1995; Mclntyre et al., 1993; Pisetsky and Reich, 1994; Zhao et al, 1995) . There are potential specific effects within this pattern of immune stimulation that appear to not to be a general P=S ODN effect. For instance, both the pattern and the kinetics of cytokine production induced by P=S ODNs are sequence dependent (Zhao et al., 1997) .
Difference in the magnitude of effects induced by the two P=S ODN sequences included the reduction in the number of platelets. CGP 69846A significantly reduced platelets while ISIS 11061 had no observed effect. Evaluation of the bone marrow was not consistent with a toxicity and reduction in platelet formation. No histopathological effects were observed in the bone marrow at 20 mg/kg and at the dose level of 100 mg/kg increased cellularity was noted. Alternatively, splenomegaly and Kupffer cell hyperplasia were more severe in the CGP 69846A-treated mice and may result in destruction or sequestration of platelets and thereby account for the observed decrease in platelets. Destruction or more rapid turnover of platelets has been suggested previously (Sarmiento et al., 1994) and would explain the increased bone marrow cellularity as a compensatory response. The association between Kupffer cell hyperplasia and splenomegaly as a possible mechanism for decrease in platelets is consistent with the findings in previous studies (Henry et al., 1997f; Sarmiento et al, 1994) .
The possibility that pronounced or prolonged inhibition of C-raf kinase expression might have deleterious effects on normal animals was addressed by evaluating the toxicity of the murine anti-c-ra/sequence, ISIS 11061. Levels of C-ra/kinase mRNA were reduced by three doses of 100 mg/kg ISIS 11061 demonstrating that the doses employed in the toxicology study were sufficient to reduce expression. Thus, it appears that there were no toxicities associated with 4 weeks of exposure to doses known to reduce C-ra/kinase mRNA levels (Fig. 1) . All the effects induced by ISIS 11061 have been observed with other P=S ODNs targeting other gene products (Henry et al, 1997c , 0-The toxicities observed with either ISIS 11061 or CGP 69846A, including hepatocellular degeneration, Kupffer cell hyperplasia, and increases in white blood cells and lymphocytes, were qualitatively similar. These data suggest that while ISIS 11061 reduced C-ra/kinase mRNA levels in mice, the toxicities observed appear to be a class effect and do not appear related to inhibition of C-raf kinase.
Toxicities observed in monkeys administered CGP 69846A have been observed before with other P=S ODNs targeting ICAM-1 and PKC-a mRNA (Henry et al, 1997a, d ). Therefore, there were no effects evident that might be attributed solely to a reduction of C-raf kinase. While at the time of initiation of the monkey study human and primate homology of an active C-raf antisense sequence was speculated, the sequence of CGP 69846A contains two mismatches from the corresponding monkey C-raf sequence. In the liver samples collected at the termination of the monkey study, no reduction of C-ra/kinase mRNA expression was apparent. The absence of C-raf mRNA reductions in monkeys could be the result of the sequence mismatches or the time at which the samples were collected (48 h after the last dose). In recently published work, a 2-bp mismatch between the baboon and human C-raf antisense sequence was identified and in this study the human antisense sequence had only minimal effects in baboon cells (Mandiyan et al, 1997) . Interestingly, the human sequence has demonstrated potential antisense effects in peripheral mononuclear cells of patients (O'Dwyer et al, 1998) . In humans, doses of CGP 69846A up to 6 mg/kg have been well tolerated as was predicted by the study with monkeys.
In these studies with animals, doses were clearly defined that were well tolerated by mice and monkeys. The toxicities associated with the administration of these C-raf antisense compounds were similar to those identified previously with other systemically administered P=S ODNs (Henry et al, 1997d) . Therefore, the toxicities in both mice and monkeys appear to be independent of pharmacologic target. Specifically in mice, where a P=S ODN sequence was demonstrated to reduce C-raf kinase mRNA, no effects were considered to result from prolonged reductions in C-raf kinase expression. Compared with existing cytotoxic agents for cancer chemotherapy, the use of antisense oligodeoxynucleotides is a less toxic approach for treatment.
